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Abstract
Pathologic conditions associated with hyperinsulinemia,
such as obesity, metabolic syndrome, and diabetes, seem to
increase the risk of breast cancer. Here, we studied molecular
mechanisms by which insulin activates the expression of
leptin, an obesity hormone that has been shown to promote
breast cancer progression in an autocrine or paracrine way.
Using MDA-MB-231 breast cancer cells, we found that (a)
insulin stimulated leptin mRNA and protein expression, which
was associated with increased activation of the leptin gene
promoter; (b) insulin increased nuclear accumulation of
transcription factors hypoxia inducible factor (HIF)-1A and
Sp1 and their loading on the leptin promoter; (c) small
interfering RNA (siRNA)-mediated knockdown of either
HIF-1A or Sp1 significantly down-regulated insulin-induced
leptin mRNA and protein expression; further inhibition of
leptin expression was observed under the combined HIF-1A
and Sp1 siRNA treatment; (d) inhibition of extracellular
signal-regulated kinase (ERK)1/2 and phosphatidylinositol-
3-OH kinase (PI-3K) pathways significantly, albeit partially,
decreased insulin-dependent leptin mRNA and protein ex-
pression, which coincided with reduced association of HIF-1A
and/or Sp1 with specific leptin promoter regions; and (e)
inhibition of ERK1/2 reduced recruitment of both HIF-1A
and Sp1 to the leptin promoter, whereas down-regulation of
PI-3K influenced only HIF-1A binding. In summary, our data
suggest that hyperinsulinemia could induce breast cancer
progression through leptin-dependent mechanisms. In
MDA-MB-231 cells, this process requires Sp1- and HIF-
1Amediated leptin gene transcription and is partially
regulated by the PI-3K and ERK1/2 pathways. [Cancer Res
2008;68(12):4919–27]
Introduction
Recent epidemiologic reports suggested that general obesity is
associated with an increased risk of developing breast cancer in
postmenopausal women, whereas central obesity can increase
breast cancer risk in both premenopausal and postmenopausal
populations (1, 2). The molecular mechanisms underlying the
obesity-breast cancer link are not clear, but it is thought that one
important factor might be excess exposure of mammary epithe-
lium to various bioactive substances ( for instance, estrogens and
growth factors) synthesized by the adipose tissue (2–5). The
principal hormone produced by adipocytes is leptin (6). Leptin, the
product of the (ob) gene, is best known as a regulator of food intake
and energy expenditure via hypothalamic-mediated effects (6).
However, leptin also controls other processes such as reproduction,
lactation, hematopoiesis, immune responses, cell differentiation,
proliferation, survival, and angiogenesis (6). Furthermore, there is
evidence that leptin can be involved in neoplastic processes (7).
Data obtained using breast cancer cellular and animal models
suggested that leptin can stimulate cell growth, survival, and
transformation, and interfere with the action of antiestrogens (2, 3,
5, 7–9).
Recently, we and others reported that leptin and its receptor
(ObR) are overexpressed in breast cancer relative to noncancer
mammary epithelium (10–12), which indicates that leptin can
influence breast cancer cells not only by endocrine and/or
paracrine actions but also through autocrine pathways. We also
showed that overexpression of leptin and ObR mRNA in breast
cancer could be induced by high doses of insulin (10). Interestingly,
although insulin was a major stimulant of leptin in less
differentiated estrogen receptor-a (ER)-negative MDA-MB-231
cells, it only modestly up-regulated leptin mRNA in less aggressive
ER-positive MCF-7 cells (10). Because hyperinsulinemia, one of the
characteristics of obesity, diabetes, and metabolic syndrome, has
been associated with increased breast cancer risk (4, 13, 14), we set
out to investigate the mechanism by which insulin up-regulates
leptin expression in ER-negative breast cancer cells.
The human leptin gene promoter ( from 2931 to +1) contains
multiple transcription regulatory elements that can be activated by
insulin. These include seven Sp1 binding sites (GC boxes) and eight
binding sties for hypoxia inducible factor (HIF; ref. 15). Sp1 is a
ubiquitous nuclear factor that mediates the effects of insulin in
different cell types, regulating such processes as glucose metabo-
lism, lipid biosynthesis (16–18). The abundance of nuclear Sp1 has
been shown to be increased by insulin and can be posttransla-
tionally regulated by phosphatidylinositol-3-OH kinase (PI-3K) and
extracellular signal-regulated kinase (ERK)1/2 pathways in some
cell models (19–21).
HIF is a transcription factor of major importance in cellular
response to oxygen deficiency, as it acts as a master regulator of
genes involved in tissue reoxygenation (22). In addition, HIF is
known to facilitate cancer progression by promoting tumor
neoangiogenesis, cell motility, and invasion (23). HIF is a
heterodimer consisting of a constitutively expressed HIF-1h
subunit and an oxygen-regulated, unstable HIF-1a subunit. HIF
interactions with DNA are mediated through Hypoxia-Responsive
Elements (HRE; 5¶-RCGTG-3¶; ref. 22). HIF activation involves
HIF-1a stabilization, which occurs either due to hypoxia or
under normoxia upon activation of different signaling pathways,
for instance, the insulin-responsive PI-3K/mammalian target of
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rapamycin and ERK1/2 cascades (24, 25). Importantly, ERK1/2
may also phosphorylate and activate the histone acetyltransfer-
ase p300 (26–28), a common coactivator of Sp1 and HIF
(28–30), leading to increased transcriptional activity of both
factors. HIF and Sp1 have been implicated in the regulation of
the leptin promoter in noncancer tissues (17, 31), according to
our recent work, HIF can induce leptin gene in breast cancer
cells (32).
Here, we show that in MDA-MB-231 breast cancer cells, insulin-
induced up-regulation of leptin expression is regulated by PI-3K
and ERK1/2 and depends on Sp1 and HIF-1a interactions with
specific regions in the leptin promoter.
Materials and Methods
Cell culture and treatments. MDA-MB-231 cells were grown in DMEM:
F12 (Cellgro) containing 5% calf serum. The cultures were synchronized in
phenol red–free serum-free medium for 24 h and then stimulated with
340 nmol/L insulin (Sigma) for 4 or 16 h, depending on the experiment.
LY294002 (LY; Calbiochem) at 50 Amol/L was used to inhibit PI-3K, whereas
UO00126 (UO; Calbiochem) at 5 Amol/L was used to down-regulate ERK1/2
activity. These doses were identified before as the most effective, nontoxic
concentrations for MDA-MB-231 cells (33).
Western blotting. The cells were stimulated with 340 nmol/L insulin for
4 h and then lysed to obtain cytoplasmic and nuclear proteins, as described
before (34). The expression of proteins was analyzed in 70 Ag of cytoplasmic
or nuclear cell lysates. The following antibodies (Ab) were used for Western
blotting (WB): HIF-1a monoclonal (m)Ab (B&D systems); Sp1 (PEP2)
polyclonal (p)Ab (Santa Cruz Biotechnology); anti–h-tubulin H235 (Santa
Cruz); and nucleolin mAb (Santa Cruz). The proteins were separated on a
4% to 15% polyacrylamide gel, immunoblotted, and quantified as described
before (34).
Luciferase reporter assays. Luciferase assays were performed as
described before (34). In brief, MDA-MB-231 cells grown in 6-well plates
were transfected for 6 h with 0.5 Ag DNA mixture per well using Fugene 6
(Roche). The transfection mixtures contained 0.3 Ag of either the leptin
promoter reporter plasmid pGL3-Ob1 encoding the firefly luciferase (Luc)
cDNA under leptin promoter ( from 2924 to +31; ref. 35) or the empty
vector pGL3. To control transfection efficiency, the cells were cotransfected
with 50 ng of pRL-TK-Luc, a plasmid encoding Renilla luciferase (RI Luc;
Promega). Upon transfection, the cells were treated with 340 nmol/L insulin
for 4 h, or left untreated. Luciferase activity (Luc and RI Luc) in cell lysates
was measured using Dual Luciferase Assay System (Promega) following the
manufacturer’s instructions and quantified as described previously (34). All
experiments were repeated at least four times.
Chromatin immunoprecipitation. We followed chromatin immuno-
precipitation (ChIP) methodology described in detail previously (34). MDA-
MB-231 cells were treated with 340 nmol/L insulin and/or 50 Amol/L LY,
5 Amol/L UO for 4 h, or left untreated. Next, the cells were crosslinked with
1% formaldehyde, and chromatin was collected and sonicated. Soluble
chromatin was immunoprecipitated with the following Abs: HIF-1a pAb
(Santa Cruz), Sp1 pAb (Santa Cruz), p300 pAb (Upstate Biotechnology), and
Histone 3 (H3) pAb (Upstate Biotechnology). DNA-protein immune
complexes were eluted, reverse crosslinked, and DNA was extracted. The
presence of leptin promoter domains containing HRE and Sp1 motifs in
immunoprecipitated DNA was identified by PCR using the following
primers: Lep1 (region from 992 to +377): forward, 5¶-GCGCAGTGGG-
GACCAGAA-3¶ and reverse, 5¶-CACCACCTCTGTGGAGTAG-3¶; Lep2 (region
from 2742 to 1403): forward, 5¶-AAAGGGCCAGGTAGAAAACAT-3¶;
reverse, 5¶-GTTTGGTAATGCCCAAAAGCT-3¶. The primers for the glyceral-
dehyde-3-phosphate dehydrogenase promoter were as follows: forward,
5¶-GCTACTAGCGGTTTTACGGG-3¶ and reverse, 5¶-AAGATGCGGCT-
GACTGTCGAA-3¶. The PCR conditions for Lep1 region were as follows:
1 min at 94jC, 1 min at 53jC, and 1 min 20 s at 72jC. For Lep2 region, the
PCR conditions were as follows: 1 min 94jC, 1 min at 60jC, and 1 min at
72jC. The amplification of Lep regions was analyzed after PCR 32 cycles. In
control samples, the primary Abs were replaced with nonimmune rabbit
IgG. All experiments were repeated at least thrice.
DNA affinity precipitation assay. Binding of nuclear HIF-1a and Sp1 to
their specific responsive elements on Lep1 (region 602 to 631 for HIF-1a
and region 354 to 323 for Sp1) and on Lep2 (region 2592 to 2562 for
HIF-1a and region2540 to 2510 for Sp1) was assessed using DNA affinity
precipitation assay (DAPA) protocol described before (32, 36). Briefly, 100 Ag
of nuclear proteins obtained from cells stimulated with 340 nmol/L insulin
and/or 50 Amol/L LY, 5 Amol/L UO for 4 h were mixed with 2 Ag of specific
biotinylated DNA HRE probes in 400 AL of Buffer D (32, 36) and then
precipitated with 50 AL of streptavidin-agarose beads (Invitrogen). Upon
removal of beads, supernatants were analyzed for the presence and
abundance of HIF-1a and Sp1 by WB. The specific HRE probes were
prepared by annealing a biotinylated sense oligonucleotide (HRE-1, HRE-2,
and HRE-3) with the corresponding nonbiotinylated antisense oligonucle-
otide. The pairs for Lep1 were as follows: for HIF-1a, 5¶-Bio-TCCAGA-
GAGCGTGCACTCCCTGGGTGCCA - 3 ¶ a n d 5 ¶- TGGCACCC -
AGGGAGTGCACGCTCTCTGGA-3 ¶; for Sp1, 5 ¶-Bio-CTCACAGC-
CACCCCCGCCCGGACCGCGCCCC-3 ¶ and 5 ¶-GGGGCGCGGT-
CCGGGCGGGGGTGGCTGTGAG-3¶. The pairs for Lep2 were as follows:
for HIF-1a, 5¶-Bio-GTAATTTTCCCGTGAGAACTATTCTTCTTT-3¶ and
5¶-AAAGAAGAATAGTTCTCACGGGAAAATTAC-3 ¶; for Sp1, 5¶-Bio-
GCGCTGATCCTCCCGCCTCAGTCTCCCTAA-3¶ and 5¶-TTAGGGAGACT-
GAGGCGGGAGGATCAGCGC-3¶. Unlabeled probes were used as negative
controls. As an additional control, a 10-fold excess of unlabeled probes was
added to the nuclear lysates 30 min before the addition of the labeled
probes to block specific probe-protein interactions, as described before (36).
All experiments were repeated at least thrice.
Leptin mRNA measurements by quantitative real-time PCR. MDA-
MB-231 cells were treated for 4 h with 340 nmol/L insulin, and/or 50 Amol/L
LY, 5 Amol/L UO for 4 h, or left untreated. For knockdown experiments, the
cells were transfected with HIF-1a siRNA and/or Sp1 siRNA (Applied
Biosystems), as described below. Total cellular RNA was isolated using
TRIzol reagent (Invitrogen). Three micrograms of total RNA were reverse
transcribed using the Taq Man RT kit (Applied Biosystems) according
to vendor’s instructions. Two microliters of the RT products were used
to amplify leptin sequences using the Hs00174877_m1 Lep Taq Man
kit (Applied Biosystems). To normalize quantitative real-time PCR
(QRT-PCR) reactions, parallel Taq Man assays were run on each sample
for a-actin. Changes in the leptin mRNA content relative to a-actin
mRNA were determined using a threshold cycle (CT) method (ABI User
Bulletin no. 2) to calculate changes in CT and, ultimately, fold and percent
change. An average CT value for each RNA was obtained for replicate
reactions.
Knockdown of HIF-1A and Sp1 using small interfering RNA. HIF-1a
and Sp1 knockdowns were achieved with specific small interfering RNA
(siRNA)s purchased fromAmbion. HIF siRNA and/or Sp1 siRNA (150 nmol/L)
was mixed with the transfection agent RNAiFect (Qiagen; siRNA to
RNAiFect ratio, 1:3) and incubated for 15 min at room temperature. Then,
the mixture was transfected into MDA-MB-231 cells for 6 h. After that, the
cells were placed in fresh medium for 24 h. Next, the cells were treated with
340 nmol/L insulin for 4 h and leptin RNA and protein levels were assessed
respectively by QRT-PCR and immunofluorescence/deconvoluted micros-
copy. In parallel, to examine the efficacy of siRNA treatments, HIF-1a and
Sp1 expression levels were determined by immunoblotting. In control
experiments, targeting siRNAs were replaced with lamin A/C siRNA
(Qiagen). The experiments were repeated thrice for HIF-1a, four times for
Sp1, and thrice for both siRNAs.
Leptin detection by immunofluorescence/deconvoluted microscopy.
MDA-MB-231 cells were plated in 2-well Permanox chamber slides (Nunc).
Subconfluent cultures were transfected with HIF-1a siRNA and/or Sp1
siRNA and treated with 340 nmol/L insulin for 16 h for leptin detection.
Then, the cells were fixed for 10 min at 20jC in methanol. Next, the cells
were permeabilized with 0.2% Triton X-100 for 5 min, and unspecific
binding was blocked with 7.5% bovine serum albumin fraction V for 1 h at
room temperature. Leptin expression was detected using 200 Ag/mL Ob
pAb A-20 (Santa Cruz) and donkey anti-rabbit IgG-FITC (Santa Cruz). The
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slides were covered with Vectashield mounting medium containing 4¶,6-
diamidino-2-phenylindole (DAPI; Vector laboratories, Inc.) to allow
visualization of cell nuclei. The abundance of leptin under different
conditions was assessed using Olympus IX81 deconvoluted microscope and
Slidebook software. Leptin expression was quantified by determining the
percentage of positive cells in at least 10 viewing fields.
Leptin detection by ELISA. Subconfluent MDA-MB-231 cells were left
untreated or were treated for 4 h with 340 nmol/L insulin, and/or 50 Amol/L
LY, 5 Amol/L UO. After that, the cells were counted and conditioned
medium was collected and concentrated with Amicon centrifugal filter 10K
(Millipore) to final volume of 500 AL. Leptin concentration in conditioned
medium was measured using the Human ELISA kit (R&D), which
specifically detects leptin without significant cross-reactivity or interference
with factors related to or associated with leptin. The lowest detectable
concentration was 7.8 pg/mL, intra-assay variation was <4.8%, and inter-
assay variation was <7.2%. The standard curve was done using 0, 7.8, 15.6,
31.2, 62.5, 125, 250, 500, and 1,000 pg/mL leptin concentrations. Leptin
concentrations detected in conditioned medium were within the range of
the standard curve. The concentrations are expressed as pg/mL per 1.5 
107 cells. All points were done in triplicate and the experiments were
repeated thrice.
Statistical analysis. The correlations were studied by Student’s t test.
P values of <0.05 were considered statistically significant.
Results
Insulin treatment activates the leptin promoter and
increases leptin mRNA and protein expression in MDA-MB-
231 cells.We have previously shown that leptin is overexpressed in
human breast cancer biopsies and that this overexpression might
be caused by obesity-related stimuli (10). Here, we focused on the
molecular mechanism of leptin activation by high doses of insulin
in MDA-MB-231 cells.
To assess whether insulin can affect leptin transcriptional
activity, we used the reporter plasmid, pGL3-OB1, containing the
luciferase gene under the control of leptin regulatory sequences
(2,924 to +31). We found that insulin significantly (by f5.5-fold)
induced luciferase activity in MDA-MB-231 breast cancer cells
transfected with pGL3-OB1, relative to cells transfected with an
empty vector pGL3 (Fig. 1A).
Using QRT-PCR, we showed that insulin stimulated leptin mRNA
synthesis by f1.8-fold, relative to untreated cells. Using immuno-
fluorescence deconvoluted microscopy, we observed that cellular
leptin protein was highly expressed in 65% F 2% of insulin-treated
cells but was detectable only in 10% F 1% of control cells (Fig. 1B
and C). Similarly, insulin significantly (f4.0-fold) increased the
levels of secreted leptin, as measured by Elisa (Fig. 1D).
Insulin stimulates nuclear expression of HIF-1A and Sp1.
Insulin can activate gene transcription through different transcrip-
tion factors, including both Sp1 and HIF-dependent mechanisms
(32, 37–40). Here, we assessed the abundance of nuclear Sp1 and
HIF-1a in MDA-MB-231 cells in response to insulin treatment
(Fig. 2A). In untreated cells, similar levels of Sp1 were found in the
cytoplasm and nucleus, whereas HIF-1a was present only in
nuclear protein fractions. Insulin stimulation significantly
increased nuclear abundance of both factors (Fig. 2A). The
cytoplsmatic protein h-tubulin and nuclear protein nucleolin were
used as control of protein loading.
Insulin stimulates loading of transcription factors on the
leptin promoter in MDA-MB-231 cells. To test if insulin
stimulates the loading of Sp1 and HIF-1a as well as other
transcription regulators on the leptin promoter, we first used
ChIP assays (Fig. 2B). Because the leptin promoter contains
multiple potential HIF and Sp1 binding sites, we hypothesized
that insulin-induced leptin transcription (Fig. 1A) might be
related to the increased association of HIF-1a and Sp1 with
leptin regulatory sequences. Indeed, insulin significantly
increased HIF-1a and Sp1 binding to two leptin promoter
regions: Lep1 region (992 to +377) containing four HRE
Figure 1. Insulin stimulates leptin promoter activity and leptin expression. A, the activation of the leptin promoter was tested in MDA-MB-231 cells with luciferase
reporter assay, as described in Materials and Methods. The cells transfected with the control plasmid (pGL3 ) or the leptin promoter-luciferase plasmid (OB1)
were treated with 340 nmol/L insulin (Ins) or left untreated (C ). Luciferase activity was calculated as relative fold induction versus untreated cells. The experiments were
repeated at least thrice. Columns, mean; bars, SD; **, P < 0.01 control plasmid versus insulin. B, the abundance of leptin mRNA was studied with QRT-PCR in
MDA-MB-231 cells untreated (c ) or treated for 4 h with different doses of insulin, as described in Materials and Methods. The graph represents the increase of leptin
mRNA relative to the increase of a-actin mRNA in the same sample F SD. **, P < 0.01, control versus insulin. C, MDA-MB-231 cells were treated for 16 h with
340 nmol/L insulin as described in Materials and Methods. The expression of leptin (green fluorescence ) in unstimulated (C ) and stimulated (Ins ) cells was assessed by
immunostaining with specific Ab and deconvoluted microscopy, as detailed in Materials and Methods. Cell nuclei were identified with DAPI (blue fluorescence ). In
control experiments (Abs C ), primary Abs were omitted. D, the levels of leptin secreted by untreated and insulin-treated cells were measured by ELISA, as described in
Materials and Methods. The values represent pg leptin/mL conditioned medium obtained from 1.5  107 cells. The differences between the two conditions were
statistically significant (P < 0.05).
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consensus sequences (765/760, 632/627, 571/566, and
120/115) and five Sp1 binding motifs (655/649, 353/
343, 128/122, 103/90, and 22/16), and Lep2 (region
from 2742 to 1403) containing two Sp1 motifs (2539/2534
and 1913/1918) and four HRE (2593/2588, 2467/2462
1830/1825, 1506/1501; Fig. 2B). Specifically, under insulin
treatment, the recruitment of HIF-1a increased by f6-fold on
Lep1 and by f3.5-fold on Lep2, relative to untreated cells.
Similarly, insulin stimulated the association of Sp1 by f3- and
f2.5-fold on Lep1 and Lep2, respectively. In parallel, we noted
an increased association of p300, a histone acetyl transferase and
a common coregulator of HIF and Sp1 (28–30) with Lep 1 and
Lep2, paralleled by higher abundance of acetylated H3 at these
regions (Fig. 2B). Samples precipitated with control IgGs did not
reveal any PCR products for Lep 1 or Lep 2 (data not shown).
Inhibition of ERK1/2 and PI-3K pathways down-regulates
insulin-dependent leptin mRNA and protein expression. Leptin
expression and activity are regulated by insulin-sensitive ERK1/2
and PI-3K/Akt signaling pathways (41, 42). Using UO and LY
inhibitors, we studied whether these pathways are required for
leptin expression in MDA-MB-231 cells. The treatment of cells with
UO inhibited insulin-induced leptin mRNA expression by f38%.
Similar effects were observed with LY (Fig. 3A). LY, but not UO, also
blocked basal leptin mRNA by f50% (Fig. 3A). Similarly, insulin-
dependent leptin levels were reduced by UO and LY by f38% and
41%, respectively, whereas basal levels were not significantly
affected (Fig. 3B).
Inhibition of PI-3K reduces insulin-dependent binding of
HIF-1A, but not of Sp1, to the proximal leptin promoter. PI-3K
and ERK-1/2 pathways are known to regulate HIF-1a expression
and activity, whereas Sp1 is influenced mostly by ERK-1/2 (43–46).
Here, we studied how inhibition of these pathways can affect
insulin-induced recruitment of HIF-1a and Sp1 to the leptin
promoter. Using ChIP technology, we found that LY significantly
(by f25%) reduced insulin-dependent binding of HIF-1a to Lep1;
however, it did not modulate binding of Sp1 to Lep1 or Lep2
regions. Samples precipitated with control IgGs did not reveal any
Lep 1 or Lep2 PCR products (Figs. 4A and 6).
Similarly, using DAPA assay, we found that LY inhibited by
f20% HIF-1a binding to 602/631 sequence in Lep1; however,
the drug did not affect HIF-1a interaction with Lep2 or Sp1
associations with any leptin promoter regions (Fig. 4B). Relevant
Figure 2. Insulin increases nuclear levels of HIF-1a and Sp1 and stimulates their loading on the leptin promoter. A, MDA-MB-231 cells were cells treated for 4 h with
340 nmol/L insulin or left untreated. The expression of HIF-1a (f120 kDa) and Sp1 (f106 kDa) was assessed by WB in 70 Ag of cytoplasmic or nuclear proteins
using specific Abs, as described in Materials and Methods. Protein loading and purity of fractions were controlled by reprobing WB filters for the expression of a
cytoplasmic protein h-tubulin (Tub ) and a nuclear marker nucleolin (Nuc ). Graphs represent relative HIF-1a and Sp1 expression levels normalized to nuclear marker
nucleolin or cytoplasmic protein h-tubulin; columns, mean; bars, SD; *, P < 0.05, control versus insulin. B, soluble chromatin was isolated from MDA-MB-231 cells
stimulated with insulin for 4 h, and from untreated cells. The binding of HIF-1a, Sp1, p300, and acetylated histones H3 (AcH3 ) to two different leptin promoter
regions, Lep1 and Lep2, was assessed by ChIP, as described in Materials and Methods. Nonimmune IgG was used as control for precipitating Abs. DNA input in PCR
reactions was assessed using Lep1 and Lep2 primers on samples before immuniprecipitations. The graph represents the abundance of HIF-1a, Sp1, AcH3, or
p300 on Lep1 and Lep2 under different conditions F SD; *, P < 0.05, control versus insulin.
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unlabeled probes, used as controls, did not precipitate HIF-1a or
Sp1 proteins (data not shown).
Inhibition of ERK-1/2 significantly reduces insulin-depen-
dent binding of HIF-1A to the proximal and distal leptin
promoter and of Sp1 to the proximal leptin promoter. In the
presence of UO, insulin-stimulated HIF-1a loading on Lep1 was
reduced by f50% and on Lep2, by f46%, according to our ChIP
analysis. UO also nearly completely blocked the basal level of HIF-
1a binding to these regions (Fig. 4A). Furthermore, UO inhibited
insulin-dependent association of Sp1 with Lep1 by f62%.
However, no effects of UO were noted for Sp1 binding to Lep2
(Fig. 4A). Samples precipitated with control IgGs did not reveal any
Lep 1 or Lep2 PCR products. Similar effects of inhibitors were
obtained in DAPA assays, where UO down-regulated HIF-1a
binding to 602/631 and 2592/2562 sequences in Lep 1 and
Lep2, respectively, and reduced the association of Sp1 to 354/
323 Lep1 region (Fig. 4B).
Insulin-induced expression of leptin in breast cancer cells
requires HIF-1A and Sp1. To determine whether HIF-1a and Sp1
are required for insulin-dependent leptin expression in breast
cancer cells, we inhibited basal and insulin-induced HIF-1a and
Sp1 expression with RNA interference. Targeting siRNAs down-
regulated basal HIF-1a and Sp1 protein levels by f98% and 85%,
respectively, whereas unrelated lamin A/C siRNAs had no effects on
these proteins (Fig. 5A ; data not shown). HIF-1a and Sp1
knockdowns were paralleled by f47% and 50% inhibition of
insulin-induced leptin mRNA levels, respectively. Using a mixture of
both siRNAs, we observed further (f70%) reduction of insulin-
dependent leptin mRNA expression (Fig. 5B). No significant effects
of single siRNAs were seen on basal leptin mRNA expression, but
the combination of both siRNAs reduced basal leptin levels by
f50% (Fig. 5B). Similarly, siRNAs targeting either HIF-1a, Sp1, or
both transcription factors reduced cellular leptin expression by
58% F 4%, 46% F 2%, and 100% F 0%, respectively (Fig. 5C).
The hypothetical model of insulin-dependent leptin expression
through Sp1- and HIF-1adependent transcription in MDA-MB-
231 cells is presented in Fig. 6.
Discussion
Pathologic conditions associated with hyperinsulinemia, such as
obesity, metabolic syndrome, and diabetes, have been shown to
increase the risk of breast cancer (1, 2, 5). Insulin is known to
stimulate breast cancer cell growth and transformation; however,
molecular mechanisms of these effects are only partially known
(47). Here, we studied how insulin activates the expression of
obesity hormone leptin in breast cancer cells.
Studies in cellular and animal models showed that leptin can
increase breast cancer cell growth, survival, tumorigenicity, and
drug resistance (2, 7). Current evidence suggests that leptin is
significantly overexpressed in breast cancer relative to noncancer
mammary epithelium (10–12). As suggested by our previous work,
leptin mRNA overexpression can be induced by obesity-related
stimuli, such as insulin, insulin-like growth factor I (IGF-I),
estrogens, or hypoxia (10). Interestingly, compared with other
mitogens or hypoxia-mimetic agents, insulin was the most effective
leptin inducer in ER-negative, metastatic MDA-MB-231 cells (10).
Our studies on the molecular mechanism of this phenomenon
revealed that: (a) in MDA-MB-231 cells, insulin stimulates leptin
mRNA and protein expression, which is associated with transcrip-
tional activation of the leptin gene promoter; (b) insulin increases
nuclear accumulation of transcription factors HIF-1a and Sp1 and
their loading on the leptin promoter, especially association of HIF-
1a with 602/631 and 2592/2562 sites, and Sp1 with 354/
323 and 2540/2510 sites; (c) siRNA-mediated knockdown of
either HIF-1a or Sp1 significantly down-regulates insulin-induced
leptin mRNA and protein expression; this effect is further amplified
by double knockdown of both factors; and (d) inhibition of ERK1/2
and PI-3K pathways partially decreases insulin-dependent leptin
expression, which is associated with reduced association of HIF-1a
and/or Sp1 with specific leptin promoter regions.
In MDA-MB-231 cells, 340 nmol/L insulin increased leptin
expression through transcriptional mechanism (Figs. 1 and 2).
Because the human leptin promoter contains multiple Sp1
binding sites and HRE motifs, we tested whether these
transcription factors are involved in insulin-induced leptin
expression. ChIP assays showed that insulin increased nuclear
abundance of both Sp1 and HIF-1a, and elevated binding of
these transcription factors to Lep1 and Lep2 promoter regions.
These effects were paralleled by increased binding of p300 and
acetylation of histone H3 (Fig. 2). Further DAPA analysis proved
that within the studied promoter regions, 602/631 and
2592/2562 were the preferential HIF-1a binding sites, and
Figure 3. Insulin-induced leptin mRNA and protein expression is mediated
by PI-3K and ERK1/2. A, MDA-MB-231 cells were treated for 4 h with
340 nmol/L insulin, and/or 50 Amol/L LY, and/or 5 Amol/L UO, as described in
Materials and Methods. The abundance of leptin mRNA was studied with
QRT-PCR in MDA-MB-231 cells untreated or treated with insulin, and/or LY,
and/or UO as described in Materials and Methods. The graph represents the
increase of leptin mRNA relative to the increase of a-actin mRNA in the same
sample FSD; *, P < 0.05 basal versus inhibitor-treated or insulin versus inhibitor-
treated. B, the cells were treated with insulin in the presence or absence of
LY or UO. Secreted leptin concentrations were measured as described in
Materials and Methods and represent pg leptin per milliliters of conditioned
medium from 1.5  107 cells. Columns, mean; bars, SDs; *, P < 0.05 basal
versus inhibitor-treated or insulin versus insulin + inhibitor–treated.
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354/323 and 2540/2510 were the sites for Sp1 binding
(Figs. 4 and 6). Interestingly, Sp1 and HIF-1a did not associate
with other individual consensus sites in response to insulin (data
not shown). This could reflect true transcriptional preferences
under insulin treatment, or be simply related to high CG content
and tertiary structures of our DNA-DAPA probes and their poor
hybridization with transcription factors in vitro . Interestingly, in
ChIP assays, loading of HIF-1a and Sp1 tended to be more
abundant on Lep1 than on Lep2, possibly due to preferential
chromatin structure within the region containing 602/631
HRE and 354/323 Sp1 motifs (Fig. 6).
The importance of HIF-1a and Sp1 for leptin mRNA and protein
expression was confirmed using specific siRNAs. Indeed, down-
regulation of both transcription factors produced nearly complete
inhibition of insulin-dependent leptin mRNA expression and
resulted in total blockade of insulin-induced leptin protein
expression (Fig. 5). This is in agreement with the notion that
HIF-1a and Sp1 cooperate in the regulation of insulin-induced
Figure 4. Insulin controls HIF-1a and Sp1 loading on the leptin promoter. A, MDA-MB-231 cells were treated for 4 h with insulin, and/or LY, and/or UO or left untreated.
The binding of HIF-1a and Sp1 to Lep1 and Lep2 regions was assessed by ChIP with specific Ab, or control IgG, as described in Materials and Methods. DNA
input in PCR reactions was assessed using Lep1 and Lep2 primers on samples before immunoprecipitations. The graph represents relative abundance of HIF-1a
and Sp1 on Lep1 and Lep2 under different conditions FSD; *, P < 0.05 basal versus inhibitor-treated or insulin versus insulin + inhibitor–treated. B, the cells were
treated as described above. The binding of nuclear HIF-1a or Sp1 to specific leptin promoter regions was analyzed by DAPA, as described in Materials and Methods.
Columns, mean; bars, SD; *, P < 0.05 basal versus treated samples.
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leptin transcription in adipocytes (17). However, effective down-
regulation of HIF-1a (98%) and Sp1 (85%) did not produce similarly
profound effects on leptin mRNA, suggesting that other transcrip-
tion factors might be involved.
The transcriptional activity of the leptin promoter seemed to be
differentially regulated by PI-3K and ERK1/2, two major pathways
activated by insulin. The ERK1/2 pathway controlled the association
of HIF-1a with Lep1 and Lep2 as well as Sp1 binding to Lep1, which
might be related to significant regulation of both factors by ERK-1/
2–dependent phosphorylation (27, 43, 44). On the other hand, PI-3K
regulated HIF-1a binding only on the proximal Lep1 promoter
region (Figs. 4 and 6). Interestingly, loading of Sp1 on Lep2 was not
blocked by the PI-3K or ERK1/2 inhibitors (Figs. 4 and 6), suggesting
that insulin used other pathways, for instance PKCa to phosphor-
ylate Sp1 and activate Sp1/DNA interaction (48). Insulin could also
affect leptin transcription through crosstalk with other receptors or
intracellular kinases, such as src. The substantial, albeit partial,
involvement of the PI-3K and ERK1/2 pathways in insulin-
dependent leptin mRNA and protein expression was confirmed by
QRT-PCR and ELISA data (Fig. 3). The basal leptin mRNA and
protein expression seemed to be regulated by HIFand Sp1, and PI-3K
could be involved on the transcriptional level (Figs. 3 and 5).
Although PI-3K might influence basal HIF activity, it is not clear
which pathways affected basal Sp1 activity.
Our results demonstrating insulin-dependent leptin transcription
in MDA-MB-231 breast cancer cells are in agreement with data
obtained in other cells models (17, 36). We are the first to show that
in MDA-MB-231 cells, insulin-induced leptin expression is regulated
by PI-3K and ERK1/2 pathways and requires Sp1- and HIF-
1amediated transcription. Previously, we showed that MCF-7
breast cancer cells can produce leptin in response to estradiol,
insulin, IGF-I treatment, as well as in response to physiologic or
pharmacologic hypoxia (10). However, in MCF-7 cells, the action of
insulin was mediated by HIF-1a, although Sp1 was not involved
(data not shown; ref. 32). This implicates that the mechanisms of
leptin synthesis in breast tumors might be cell context–dependent;
Figure 5. HIF-1a and Sp1 knockdowns
reduce leptin expression. A, MDA-MB-231
cells were transfected with HIF-1a or Sp1
siRNA, as described in Materials and
Methods, or were left untransfected. In
control experiments, the cells were
transfected with lamin A/C siRNA. The
expression of HIF-1a and Sp1 in 50 Ag of
total cell lysates was determined by WB.
Columns, mean; bars, SD; *, P < 0.05
control versus treated samples. B, the
expression of leptin mRNA in HIF-1a and
Sp1 siRNA transfectants treated with
insulin for 4 h or left untreated was
studied by QRT-PCR. Columns, mean;
bars, SD; *, P < 0.05 basal versus treated
or insulin versus treated samples. C , the
expression of leptin protein after 16 h
of insulin treatment was visualized by
immunofluorescence and deconvoluted
microscopy. The expression of h-tubulin
was assessed as control of protein loading.
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for instance, the process is somehow dependent on the presence
or absence of ER, as this receptor is know to influence insulin and
IGF-I signaling pathways and their outcome (33, 49).
In summary, our data suggest that hyperinsulinemia could induce
breast cancer progression through leptin-dependent mechanisms.
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Figure 6. Model of insulin-induced leptin transcription in MDA-MB-231 cells. Insulin induces HIF-1a and Sp1 binding with the leptin promoter regions Lep1 and Lep2.
Potential HIF-1a and Sp1 binding sites are indicated by open ovals or rectangles, respectively, whereas identified by DAPA sites are indicated by black shapes.
Association of HIF-1a with Lep1 is controlled in part by PI-3K and ERK1/2. Binding of Sp1 to Lep1 is enhanced by ERK-1/2. On Lep2, binding of HIF-1a is partially
controlled by ERK1/2, whereas neither PI-3K nor ERK1/2 modulates Sp1 association.
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